卢比通通过准多个炎症途径来增强MTX的抗风湿性关节炎活性
Ziyu Li1, Qiuyan Zhang2, Yuhe Gao3
1Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, People's Republic of China.
Journal of inflammation research
|July 12, 2024
概括
罗比 (LBT) 与甲索特酸相结合,通过向多个炎症途径,有效治疗类风湿性关节炎. 这种新的传统中医药显示出显著的治疗潜力,没有任何不良影响.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 洛比通 (LBT) 是一种新的传统中医药配方,目前正在治疗类风湿性关节炎 (RA) 的第三期试验中.
- 以前的研究表明,LBT在RA治疗中的有效性和安全性.
- 在RA中LBT作用的精确机制需要进一步阐明.
研究的目的:
- 为了研究LBT的治疗效果和潜在机制,结合维护剂量的甲醇 (M-MTX) 治疗RA.
- 探索如何LBT调节炎症途径在RA治疗的背景下.
主要方法:
- 用一种原诱导关节炎 (CIA) 鼠标模型来评估LBT + M-MTX.的抗RA作用.
- 评估包括临床评估 (胀,得分),血清细胞因子分析和组织病理学.
- 网络药理学预测了潜在的机制,而流动细胞计,西部斑块和免疫组织化学确定了向的炎症途径.
主要成果:
- LBT + M-MTX显著缓解了CIA诱导的关节炎,没有任何不良影响.
- 组合疗法显示,对巨细胞极化,NF-κB,MAPK信号传递和TH-17抑制的调节相当或优越.
- 这些结果表明LBT在RA中的多途径治疗效果.
结论:
- 结合甲醇,LBT通过多途径调制增强了抗RA效应.
- 在类风湿性关节炎治疗中,LBT具有显著的治疗潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
128
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
128
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Antiasthma Drugs: Leukotriene Modifiers
269
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
269


